High energy phosphate abnormalities normalize after antipsychotic treatment in schizophrenia: A longitudinal 31P MRS study of basal ganglia

Psychiatry Research - Neuroimaging

Volumn 181, Issue 3, 2010, Pages 237-240

  Jayakumar, Peruvumba N ^a   Gangadhar, Bangalore N ^a   Venkatasubramanian, Ganesan ^a   Desai, Sunali ^a   Velayudhan, Latha ^a   Subbakrishna, Dattathreya ^a   Keshavan, Matcheri S ^b,c  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

31P Magnetic Resonance Spectroscopy; High energy phosphates; Schizophrenia

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; ARTICLE; BASAL GANGLION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ENERGY; FEMALE; HUMAN; HYPERMETABOLISM; LONGITUDINAL STUDY; MALE; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SCHIZOPHRENIA;

ADENOSINE TRIPHOSPHATE; ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; ASPARTIC ACID; BASAL GANGLIA; FEMALE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PHOSPHOCREATINE; PHOSPHORUS ISOTOPES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; YOUNG ADULT;

EID: 76849086716     PISSN: 09254927     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2009.10.010     Document Type: Article

References (21)

1. Bertolino A., Callicott J.H., Mattay V.S., Weidenhammer K.M., Rakow R., Egan M.F., and Weinberger D.R. The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biological Psychiatry 49 (2001) 39-46
2. Bustillo J.R., Lauriello J., Rowland L.M., Jung R.E., Petropoulos H., Hart B.L., Blanchard J., Keith S.J., and Brooks W.M. Effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia. Psychiatry Research: Neuroimaging 107 (2001) 135-149
3. Bustillo J.R., Lauriello J., Rowland L.M., Thomson L.M., Petropoulos H., Hammond R., Hart B., and Brooks W.M. Longitudinal follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure. Schizophrenia Research 58 (2002) 313-321
4. Bustillo J.R., Rowland L.M., Jung R., Brooks W.M., Qualls C., Hammond R., Hart B., and Lauriello J. Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia. Neuropsychopharmacology 33 (2008) 2456-2466
5. Deicken R.F., Calabrese G., Merrin E.L., Meyerhoff D.J., Dillon W.P., Weiner M.W., and Fein G. 31phosphorus magnetic resonance spectroscopy of the frontal and parietal lobes in chronic schizophrenia. Biological Psychiatry 36 (1994) 503-510
6. Ende G., Braus D.F., Walter S., Weber-Fahr W., Soher B., Maudsley A.A., and Henn F.A. Effects of age, medication, and illness duration on the N-acetyl aspartate signal of the anterior cingulate region in schizophrenia. Schizophrenia Research 41 (2000) 389-395
7. Erecinska M., and Silver I.A. ATP and brain function. Journal of Cerebral Blood Flow and Metabolism 9 (1989) 2-19
8. Fannon D., Simmons A., Tennakoon L., O'Ceallaigh S., Sumich A., Doku V., Shew C., and Sharma T. Selective deficit of hippocampal N-acetylaspartate in antipsychotic-naive patients with schizophrenia. Biological Psychiatry 54 (2003) 587-598
9. Gangadhar B.N., Jayakumar P.N., Subbakrishna D.K., Janakiramaiah N., and Keshavan M.S. Basal ganglia high-energy phosphate metabolism in neuroleptic-naive patients with schizophrenia: a 31-phosphorus magnetic resonance spectroscopic study. American Journal of Psychiatry 161 (2004) 1304-1306
10. Goto N., Yoshimura R., Moriya J., Kakeda S., Ueda N., Ikenouchi-Sugita A., Umene-Nakano W., Hayashi K., Oonari N., Korogi Y., and Nakamura J. Reduction of brain gamma-aminobutyric acid (GABA) concentrations in early-stage schizophrenia patients: 3T Proton MRS study. Schizophrenia Research 112 (2009) 192-193
11. Jayakumar P.N., Gangadhar B.N., Subbakrishna D.K., Janakiramaiah N., Srinivas J.S., and Keshavan M.S. Membrane phospholipid abnormalities of basal ganglia in never-treated schizophrenia: a 31P magnetic resonance spectroscopy study. Biological Psychiatry 54 (2003) 491-494
12. Jensen J.E., Miller J., Williamson P.C., Neufeld R.W., Menon R.S., Malla A., Manchanda R., Schaefer B., Densmore M., and Drost D.J. Grey and white matter differences in brain energy metabolism in first episode schizophrenia: 31P-MRS chemical shift imaging at 4 Tesla. Psychiatry Research: Neuroimaging 146 (2006) 127-135
13. Kemp G.J. Non-invasive methods for studying brain energy metabolism: what they show and what it means. Developmental Neuroscience 22 (2000) 418-428
14. Keshavan M.S., Bagwell W.W., Haas G.L., Sweeney J.A., Schooler N.R., and Pettegrew J.W. Changes in caudate volume with neuroleptic treatment. Lancet 344 (1994) 1434
15. Keshavan M.S., Rosenberg D., Sweeney J.A., and Pettegrew J.W. Decreased caudate volume in neuroleptic-naive psychotic patients. American Journal of Psychiatry 155 (1998) 774-778
16. Klunk W.E., Xu C.J., Panchalingam K., McClure R.J., and Pettegrew J.W. Analysis of magnetic resonance spectra by mole percent: comparison to absolute units. Neurobiology of Aging 15 (1994) 133-140
17. Klushnik T.P., Spunde A., Yakovlev A.G., Khuchua Z.A., Saks V.A., and Vartanyan M.E. Intracellular alterations of the creatine kinase isoforms in brains of schizophrenic patients. Molecular Chemistry and Neuropathology 15 (1991) 271-280
18. Leung T.K., Hall C., Monfries C., and Lim L. Trifluoperazine activates and releases latent ATP-generating enzymes associated with the synaptic plasma membrane. Journal of Neurochemistry 49 (1987) 232-238
19. Sauter A., and Rudin M. Determination of creatine kinase kinetic parameters in rat brain by NMR magnetization transfer Correlation with brain function. Journal of Biological Chemistry 268 (1993) 13166-13171
20. Volz H.P., Rossger G., Riehemann S., Hubner G., Maurer I., Wenda B., Rzanny R., Kaiser W.A., and Sauer H. Increase of phosphodiesters during neuroleptic treatment of schizophrenics: a longitudinal 31P-magnetic resonance spectroscopic study. Biological Psychiatry 45 (1999) 1221-1225
21. Volz H.P., Rzanny R., Rossger G., Hubner G., Kreitschmann-Andermahr I., Kaiser W.A., and Sauer H. Decreased energy demanding processes in the frontal lobes of schizophrenics due to neuroleptics? A 31P-magneto-resonance spectroscopic study. Psychiatry Research: Neuroimaging 76 (1997) 123-129